Roth, G. A. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736–1788 (2018).
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596–e646 (2019).
DeFilippis, A. P. et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann. Intern. Med. 162, 266–275 (2015).
Patel, A. P., Wang, M., Kartoun, U., Ng, K. & Khera, A. V. Quantifying and understanding the higher risk of atherosclerotic cardiovascular disease among South Asian individuals. Circulation 144, 410–422 (2021).
Goff David, C. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation 129, S49–S73 (2014).
Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. Br. Med. J. 357, j2099 (2017).
Emdin, C. A. et al. Polygenic score assessed in young adulthood and onset of subclinical atherosclerosis and coronary heart disease. J. Am. Coll. Cardiol. 80, 280–282 (2022).
Inouye, M. et al. Genomic risk prediction of coronary artery disease in 480,000 adults. J. Am. Coll. Cardiol. 72, 1883–1893 (2018).
Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219–1224 (2018).
Hindy, G. et al. Genome-wide polygenic score, clinical risk factors, and long-term trajectories of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 40, 2738–2746 (2020).
Sun, L. et al. Polygenic risk scores in cardiovascular risk prediction: a cohort study and modelling analyses. PLoS Med. 18, e1003498 (2021).
Hao, L. et al. Development of a clinical polygenic risk score assay and reporting workflow. Nat. Med. 28, 1006–1013 (2022).
Maamari, D. J. et al. Clinical implementation of combined monogenic and polygenic risk disclosure for coronary artery disease. JACC Adv. 1, 1–11 (2022).
Patel, A. P. & Khera, A. V. Advances and applications of polygenic scores for coronary artery disease. Annu. Rev. Med. 74, 141–154 (2023).
Zhang, Y., Qi, G., Park, J.-H. & Chatterjee, N. Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. Nat. Genet. 50, 1318–1326 (2018).
Ruan, Y. et al. Improving polygenic prediction in ancestrally diverse populations. Nat. Genet. 54, 573–580 (2022).
Weissbrod, O. et al. Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores. Nat. Genet. 54, 450–458 (2022).
Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236–1241 (2015).
Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic correlations across human complex traits. Nat. Genet. 52, 859–864 (2020).
Martin, A. R. et al. Current clinical use of polygenic scores will risk exacerbating health disparities. Nat. Genet. 51, 584–591 (2019).
All of Us Research Program Investigators et al. The ‘All of Us’ research program. N. Engl. J. Med. 381, 668–676 (2019).
Fatumo, S. et al. Promoting the genomic revolution in Africa through the Nigerian 100K Genome Project. Nat. Genet. 54, 531–536 (2022).
Elliott, J. et al. Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease. JAMA 323, 636–645 (2020).
Riveros-Mckay, F. et al. Integrated polygenic tool substantially enhances coronary artery disease prediction. Circ. Genom. Precis. Med. 14, e003304 (2021).
Weale, M. E. et al. Validation of an integrated risk tool, including polygenic risk score, for atherosclerotic cardiovascular disease in multiple ethnicities and ancestries. Am. J. Cardiol. 148, 157–164 (2021).
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
Aragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat. Genet. 54, 1803–1815 (2022).
Lambert, S. A. et al. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat. Genet. 53, 420–425 (2021).
Manikpurage, H. D. et al. Polygenic risk score for coronary artery disease improves the prediction of early-onset myocardial infarction and mortality in men. Circ. Genom. Precis. Med. 14, e003452 (2021).
Neumann, J. T. et al. Prognostic value of a polygenic risk score for coronary heart disease in individuals aged 70 years and older. Circ. Genom. Precis. Med. 15, e003429 (2022).
Gaziano, J. M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 70, 214–223 (2016).
Finer, S. et al. Cohort Profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. Int. J. Epidemiol. 49, 20–21i (2020).
Tcheandjieu, C. et al. Large-scale genome-wide association study of coronary artery disease in genetically diverse populations. Nat. Med. 28, 1679–1692 (2022).
Huang, Q. Q. et al. Transferability of genetic loci and polygenic scores for cardiometabolic traits in British Pakistani and Bangladeshi individuals. Nat. Commun. 13, 4664 (2022).
Dron, J. S. et al. Association of rare protein-truncating DNA variants in APOB or PCSK9 with low-density lipoprotein cholesterol level and risk of coronary heart disease. JAMA Cardiol. 8, 258–267 (2023).
Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
Howe, L. J. et al. Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases. Hum. Mol. Genet 29, 1388–1395 (2020).
Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415–1424 (2021).
Locke, A. E. et al. Exome sequencing of Finnish isolates enhances rare-variant association power. Nature 572, 323–328 (2019).
Zdravkovic, S. et al. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J. Intern Med 252, 247–254 (2002).
Zhang, H. et al. Novel methods for multi-ancestry polygenic prediction and their evaluations in 5.1 million individuals of diverse ancestry. Preprint at bioRxiv https://doi.org/10.1101/2022.03.24.485519 (2023).
Myers, P. D. et al. Identifying unreliable predictions in clinical risk models. NPJ Digit. Med. 3, 1–8 (2020).
Wand, H. et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature 591, 211–219 (2021).
Brockman, D. G. et al. Design and user experience testing of a polygenic score report: a qualitative study of prospective users. BMC Med. Genomics 14, 238 (2021).
Ding, Y. et al. Polygenic scoring accuracy varies across the genetic ancestry continuum. Nature https://doi.org/10.1038/s41586-023-06079-4 (2023).
Linder, J. E. et al. Returning integrated genomic risk and clinical recommendations: the eMERGE study. Genet. Med. 25, 100006 (2023).
O’Sullivan, J. W. et al. Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 146, e93–e118 (2022).
Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016).
Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017).
Aragam, K. G. et al. Limitations of contemporary guidelines for managing patients at high genetic risk of coronary artery disease. J. Am. Coll. Cardiol. 75, 2769–2780 (2020).
Fahed, A. C., Philippakis, A. A. & Khera, A. V. The potential of polygenic scores to improve cost and efficiency of clinical trials. Nat. Commun. 13, 2922 (2022).
Marston, N. A. et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial. Circulation 141, 616–623 (2020).
Damask, A. et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation 141, 624–636 (2020).
Cook, N. R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115, 928–935 (2007).
Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017).
Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508–518 (2023).
Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206 (2015).
Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat. Genet. 50, 524–537 (2018).
Zhou, W. et al. Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. Cell Genomics 2, 100192 (2022).
Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 52, 680–691 (2020).
Spracklen, C. N. et al. Identification of type 2 diabetes loci in 433,540 East Asian individuals. Nature 582, 240–245 (2020).
Klarin, D. et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. Nat. Med. 25, 1274–1279 (2019).
Hellwege, J. N. et al. Mapping eGFR loci to the renal transcriptome and phenome in the VA Million Veteran Program. Nat. Commun. 10, 3842 (2019).
Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat. Genet. 50, 1412–1425 (2018).
Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675–679 (2021).
Klarin, D. et al. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat. Genet. 50, 1514–1523 (2018).
Koyama, S. et al. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat. Genet. 52, 1169–1177 (2020).
Ye, Y. et al. Interactions between enhanced polygenic risk scores and lifestyle for cardiovascular disease, diabetes, and lipid levels. Circ. Genom. Precis. Med. 14, e003128 (2021).
Tamlander, M. et al. Integration of questionnaire-based risk factors improves polygenic risk scores for human coronary heart disease and type 2 diabetes. Commun. Biol. 5, 158 (2022).
Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
Patel, A. P. et al. Association of rare pathogenic DNA variants for familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and lynch syndrome with disease risk in adults according to family history. JAMA Netw. Open 3, e203959 (2020).
Fahed, A. C. et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat. Commun. 11, 3635 (2020).
Patel, A. P. et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler. Thromb. Vasc. Biol. 41, 465–474 (2021).
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. Bioinformatics https://doi.org/10.1093/bioinformatics/btaa1029 (2020).
International HapMap Consortium. The International HapMap Project. Nature 426, 789–796 (2003).
Vilhjálmsson, B. J. et al. Modeling linkage disequilibrium increases accuracy of polygenic risk scores. Am. J. Hum. Genet 97, 576–592 (2015).
Band, G. & Marchini, J. BGEN: a binary file format for imputed genotype and haplotype data. Preprint at bioRxiv https://doi.org/10.1101/308296 (2018).
Danecek, P. et al. Twelve years of SAMtools and BCFtools. GigaScience 10, giab008 (2021).
Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet 81, 559–575 (2007).
Zhang, Z. Variable selection with stepwise and best subset approaches. Ann. Transl. Med 4, 136 (2016).
Giri, A. et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. Nat. Genet. 51, 51–62 (2019).
Wang, M. et al. Validation of a genome-wide polygenic score for coronary artery disease in South Asians. J. Am. Coll. Cardiol. 76, 703–714 (2020).
Mega, J. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy. Lancet 385, 2264–2271 (2015).
Abraham, G. et al. Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke. Nat. Commun. 10, 5819 (2019).
Ripatti, S. et al. A multilocus genetic risk score for coronary heart disease: case–control and prospective cohort analyses. Lancet 376, 1393–1400 (2010).
Tikkanen, E., Havulinna, A. S., Palotie, A., Salomaa, V. & Ripatti, S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 33, 2261–2266 (2013).
Tada, H. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur. Heart J. 37, 561–567 (2016).
Paquette, M. et al. Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. J. Clin. Lipidol. 11, 725–732.e5 (2017).
Hajek, C. et al. Coronary heart disease genetic risk score predicts cardiovascular disease risk in men, not women. Circ. Genom. Precis. Med. 11, e002324 (2018).
Pechlivanis, S. et al. Risk prediction for coronary heart disease by a genetic risk score—results from the Heinz Nixdorf Recall study. BMC Med. Genet. 21, 178 (2020).
Gola, D. et al. Population bias in polygenic risk prediction models for coronary artery disease. Circ. Genom. Precis. Med. 13, e002932 (2020).
Bauer, A. et al. Comparison of genetic risk prediction models to improve prediction of coronary heart disease in two large cohorts of the MONICA/KORA study. Genet. Epidemiol. 45, 633–650 (2021).
Mars, N. et al. Genome-wide risk prediction of common diseases across ancestries in one million people. Cell Genom. 2, 100118 (2022).
Lu, X. et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. Eur. Heart J. 43, 1702–1711 (2022).
McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–1283 (2016).
Walter, K. et al. The UK10K project identifies rare variants in health and disease. Nature 526, 82–90 (2015).
Hunter-Zinck, H. et al. Genotyping array design and data quality control in the Million Veteran Program. Am. J. Hum. Genet. 106, 535–548 (2020).
Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of determination for genetic profile analysis. Genet. Epidemiol. 36, 214–224 (2012).
